Novo Nordisk to cut 9,000 jobs in major restructuring drive

Novo Nordisk announced plans to cut 9,000 jobs, approximately 12% of its global workforce, as part of a major restructuring aimed at sharpening its focus on core obesity and diabetes treatments. This strategic initiative, the first under new CEO Maziar Mike Doustdar, is driven by increasing competition, particularly in the US weight-loss market, and ongoing supply chain disruptions. The company anticipates a one-time cost of $1.3 billion from the cuts, leading to a revised 2025 operating profit growth forecast of 4-10%, down from a previous 10-16%.

Analysis

Novo Nordisk (NVO) is undertaking a significant corporate restructuring, marked by a 9,000-role reduction, or 12% of its global workforce. This strategic overhaul, the first major initiative under new CEO Maziar Mike Doustdar, is aimed at sharpening the company's focus on its core obesity and diabetes treatments. The restructuring carries a material financial impact, with an anticipated one-time cost of $1.3 billion directly causing a downward revision of the 2025 operating profit growth forecast to 4%-10%, a significant reduction from the prior 10%-16% range. This move is a direct response to mounting external pressures, including growing competition in the U.S. weight-loss market and ongoing supply chain disruptions, as the company seeks to improve efficiency and reallocate capital.

Key Decisions for Investors

• Investors should anticipate near-term negative pressure on NVO's share price, driven by the substantial downward revision of its 2025 operating profit growth guidance.
• The long-term investment thesis now hinges on the successful execution of this restructuring by the new leadership to defend market share and improve margins against intensifying competition.
• Monitor competitive developments in the U.S. and any updates on supply chain resolutions, as these are the primary external risks that prompted this defensive corporate action.